Your browser doesn't support javascript.
loading
Next generation L2-based HPV vaccines cross-protect against cutaneous papillomavirus infection and tumor development.
Ahmels, Melinda; Mariz, Filipe C; Braspenning-Wesch, Ilona; Stephan, Sonja; Huber, Bettina; Schmidt, Gabriele; Cao, Rui; Müller, Martin; Kirnbauer, Reinhard; Rösl, Frank; Hasche, Daniel.
Afiliação
  • Ahmels M; Division of Viral Transformation Mechanisms, Research Program "Infection, Inflammation and Cancer", German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Mariz FC; Research Group Tumorvirus-specific Vaccination Strategies, Research Program "Infection, Inflammation and Cancer", German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Braspenning-Wesch I; Division of Viral Transformation Mechanisms, Research Program "Infection, Inflammation and Cancer", German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Stephan S; Division of Viral Transformation Mechanisms, Research Program "Infection, Inflammation and Cancer", German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Huber B; Laboratory of Viral Oncology, Department of Dermatology, Medical University of Vienna, Vienna, Austria.
  • Schmidt G; Core Facility Unit Light Microscopy, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Cao R; Division of Viral Transformation Mechanisms, Research Program "Infection, Inflammation and Cancer", German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Müller M; Research Group Tumorvirus-specific Vaccination Strategies, Research Program "Infection, Inflammation and Cancer", German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Kirnbauer R; Laboratory of Viral Oncology, Department of Dermatology, Medical University of Vienna, Vienna, Austria.
  • Rösl F; Division of Viral Transformation Mechanisms, Research Program "Infection, Inflammation and Cancer", German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Hasche D; Division of Viral Transformation Mechanisms, Research Program "Infection, Inflammation and Cancer", German Cancer Research Center (DKFZ), Heidelberg, Germany.
Front Immunol ; 13: 1010790, 2022.
Article em En | MEDLINE | ID: mdl-36263027
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Proteínas Oncogênicas Virais / Infecções por Papillomavirus / Vacinas contra Papillomavirus / Vacinas de Partículas Semelhantes a Vírus / Neoplasias Limite: Animals / Humans Idioma: En Revista: Front Immunol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Alemanha
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Proteínas Oncogênicas Virais / Infecções por Papillomavirus / Vacinas contra Papillomavirus / Vacinas de Partículas Semelhantes a Vírus / Neoplasias Limite: Animals / Humans Idioma: En Revista: Front Immunol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Alemanha